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The Antihypertensive and Lipid-Lowering treatment toprevent Heart Attack Trial (ALLHAT) compared in30 000 high-risk hypertensive patients the effects on
coronary heart disease of 3 treatment strategies: (1) based on the
diuretic chlorthalidone, (2) the calcium-channel blocker (CCB)
amlodipine, and (3) the angiotensin converting-enzyme (ACE)
inhibitor lisinopril, respectively.1 Sponsored by the National
Heart, Lung, and Blood Institute, ALLHAT stands out because
no differences occurred in the incidence of the primary end point
that consisted of the combination of fatal coronary heart disease
and acute myocardial infarction.1 Not surprisingly, the attention
of the ALLHAT consortium shifted to secondary end points,
such as stroke, or to loosely defined2 components of secondary
end points, such as heart failure. At the end of the line, the
ALLHAT investigators based their main conclusions on events
that, at the initiation of the trial, they regarded as “soft data that
will at best confirm or supplement the primary endpoint.”3 More
importantly, what was not identical in the 3 treatment groups
was the on-treatment blood pressure despite vigorous attempts to
titrate and combine the study medications to achieve a blood
pressure of 140 mm Hg systolic and 90 mm Hg diastolic.1
These salient features of ALLHAT should be kept in mind
whenever one attempts to interpret the findings of this
landmark trial.
In this issue of Hypertension, Leenen et al4 published a post
hoc analysis, in which they made a direct comparison of
cardiovascular and other outcomes among the 18 102 ALLHAT
participants randomly assigned to amlodipine or lisinopril. In
line with previous reports,1 the incidence of the primary coro-
nary end point and total and cardiovascular mortality were
similar in both groups. However, the patients randomly assigned
to lisinopril experienced higher risks of stroke, combined car-
diovascular disease, gastrointestinal bleeding, and angioedema,
whereas the risk of heart failure was higher in the amlodipine
group.4 The excess cardiovascular risk was particularly apparent
in women and black patients. Leenen et al4 concluded that
“considering the totality of outcome measures in ALLHAT,
amlodipine appeared to have advantages over lisinopril.” This is
a provocative statement that is in line with the published
literature (Table) and that is prone to at least dent, if not shatter,
the halo surrounding the ACE inhibitors. The conclusions of
Leenen et al4 underscore the difficulty in bridging the gap
between scientifically attractive pathogenetic concepts based on
experimental models5 and the clinical reality that matters to
patients, that is, event-free survival.
The ALLHAT investigators attributed at least part of the
better cardiovascular outcome on amlodipine compared with
lisinopril to the more pronounced blood pressure reduction on
the CCB, particularly in women and black patients.4 The Heart
Outcomes Prevention Evaluation study (HOPE)6 and the Losar-
tan Intervention For Endpoint reduction in hypertension study
(LIFE)7 launched the notion of benefit beyond blood pressure
lowering, although in both trials the baseline-adjusted systolic
blood pressure at the last visit was significantly lower in the
patients randomly assigned to the ACE inhibitor (3.0 mm Hg;
P0.001)6 or the angiotensin II receptor blocker (1.3 mm Hg;
P0.017)7 than in those allocated placebo6 or atenolol,7 respec-
tively. Stroke is the complication of hypertension that is most
directly linked to the blood pressure level.8 Not surprisingly,
metaregression analyses published by us9,10 and other research-
ers11 demonstrated that, in keeping with large-scale prospective
observational studies12 and also in randomized clinical trials,
small gradients in the achieved systolic blood pressure explain
most of the differences in the cardiovascular outcomes. An
updated metaregression analysis13 accounted not only for the
differences in the achieved systolic blood pressure between
groups randomly assigned in clinical trials but also for drug
class, the interaction between on-treatment systolic pressure and
drug class, age at randomization, year of publication, and
duration of follow-up. The updated results corroborated that
blood pressure reduction was by far the most important deter-
minant of cardiovascular outcome.13 In keeping with the current
ALLHAT findings, CCBs compared with ACE inhibitors pro-
vided a small blood pressure–independent benefit (14%;
P0.042) in the prevention of stroke, and the same was true for
ACE inhibitors compared with CCBs in relation to coronary
heart disease (10%; P0.028).13 The observation that the
incidence of the primary end point was similar in the 2 treatment
groups in the study of Leenen et al4 might be interpreted as
indirect evidence suggesting that lisinopril-based therapy con-
ferred greater cardiac benefit than treatment initiated with
amlodipine.
In 2003, the Blood Pressure Lowering Trialists’ Collabo-
ration noticed that for every outcome other than heart failure,
the differences between randomized groups in cardiovascular
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outcomes were directly related to the achieved systolic blood
pressure.11 However, the lack of association among 34
reviewed trails was mainly because of the noise of 4 that
compared CCBs to placebo. The summary statistic breaking
the relationship included results from a primary prevention
trial in older patients and from 3 secondary prevention studies
in diabetic patients with renal dysfunction or in high-risk
patients with coronary heart disease.11 Substantial differences
in the pathogenetic mechanisms causing left ventricular failure
in such heterogeneous conditions cast doubt on the proposed
conclusion of no association between the prevention of heart
failure and the level of achieved systolic blood pressure.11 In the
Anglo-Scandinavian Cardiac Outcomes Trial–Blood Pressure
Lowering Arm (ASCOT-BPLA)14 and in A Coronary disease
Trial Investigating Outcome with Nifedipine gastrointestinal
therapeutic system (ACTION),15 the relative risks of heart
failure were slightly (hazard ratio: 0.84; 95% CI: 0.66 to 1.05;
P0.13)14 or significantly (hazard ratio: 0.71; 95% CI: 0.54 to
0.94; P0.015)15 lower for the CCB compared with atenolol14
or placebo15 and followed the gradients in systolic blood
pressure, amounting to 2.7 mm Hg14 and 6.0 mm Hg,15 respec-
tively. In line with the epidemiological evidence linking heart
failure to hypertension, these observations14,15 suggest that blood
pressure lowering by a CCB or any other class of antihyperten-
sive agents contributes to the prevention of left ventricular
dysfunction.
Remarkably, in ALLHAT,1,4 as well as in the Valsartan
Antihypertensive Long-term Use Evaluation trial (VALUE),16
heart failure, against the blood pressure gradient, occurred more
frequently on amlodipine than on lisinopril1,4 or valsartan.16 This
could either indicate that, for a given fall in blood pressure,
blockers of the renin–angiotensin system are more powerful in
preventing heart failure than are CCBs or that blood pressure is
a less important predictor of congestive heart failure than of
heart attack and stroke. However, in both trials,1,4,16 the Kaplan–
Meier estimates for heart failure only started to diverge after 2 to
3 years, when, compared with the amlodipine arm, a greater
proportion of patients randomly assigned to the ACE inhibitor1,4
or the angiotensin II receptor blocker16 had stopped the alterna-
tive first-line treatment, had crossed over, and/or were receiving
combination therapy, including second-line antihypertensive
medications.
Most clinicians regard ACE inhibitors as being well-tolerated
antihypertensive drugs. Unexpectedly, in the current ALLHAT
report, adherence to randomized treatment was significantly
lower in the lisinopril than in the amlodipine arm (at 5 years,
72.6% versus 80.4%). Persistence was lowest in women and
blacks. The reason for this difference is unclear but is likely to
be because of adverse effects, frequently dry cough on ACE
inhibitors and ankle edema on CCBs. For drugs that are used by
hypertensive patients over decades, long-term safety is of para-
mount concern. Angioedema is a well-documented but rare
adverse event in patients taking ACE inhibitors. It can appear
from a few hours to 8 years after an ACE inhibitor is first taken.
Unfortunately, a median of 10 months may elapse before onset
of angioedema and withdrawal of the ACE inhibitor.17 This
potentially fatal adverse event was observed in 38 patients in the
lisinopril group but only in 3 randomly assigned to amlodipine.
In the lisinopril arm, the rates were 0.72% in blacks and 0.26%
in nonblacks. Although fatalities of angioedema are exceedingly
rare, one should consider that as worldwide 30 to 40 million
patients are exposed to ACE inhibitors, this drug class might
account for several hundred fatalities per year.18 That these are
not just hypothetical numbers is underscored by instances of
fatal angioedema in both ALLHAT1,4 and HOPE6 and also by a
recent report from a single coroner’s office describing 7 cases of
asphyxiation associated with ACE inhibitors within a mere
3-year period of time.19
Finally, how should clinicians translate the new ALLHAT
findings in their day-to-day practice? Foremost, they should
be aware that high blood pressure is a reversible risk factor
with lower levels leading to fewer strokes and heart attacks.
Furthermore, several landmark trials, over and above those
listed in the Table (for review, see Reference 10), proved in
no uncertain terms that CCBs are powerful, efficacious, and
safe antihypertensive drugs and that they can be prescribed to
high-risk patients as first-line drugs for indications that were
until now dominated by inhibitors of the renin–angiotensin
Amlodipine Versus Other Reference Treatment in the Prevention of Myocardial Infarction or Stroke
Comparator Trial N
Coronary Heart Disease Stroke
OR (95% CI) P OR (95% CI) P
Versus placebo PREVENT 825
CAMELOT 1318 0.69 (0.49 to 0.97) 0.031 0.60 (0.36 to 0.98) 0.038
IDNT 1136
Versus diuretics/-blockers ALLHAT 24309
ASCOT 19257 0.96 (0.89 to 1.03) 0.26 0.86 (0.78 to 0.95) 0.002
Versus ACE inhibitors ALLHAT 18102
CAMELOT 1336 1.01 (0.91 to 1.12) 0.89 0.82 (0.71 to 0.94) 0.004
Versus angiotensin II receptor blockers IDNT 1146
VALUE 15245 0.82 (0.71 to 0.96) 0.009 0.84 (0.72 to 0.99) 0.032
N indicates the number of patients included from each trial; OR, odds ratio. Pooled ORs with 95% CIs were computed from the
number of events (amlodipine/reference) and the number of patients per group randomly assigned in each trial by use of stratified
22 contingency tables. Coronary heart disease included coronary mortality and acute myocardial infarction in ALLHAT and ASCOT;
fatal and nonfatal myocardial infarction in CAMELOT, IDNT, PREVENT, and VALUE; and nonfatal myocardial infarction in CAMELOT. The
trial acronyms are given in Reference.10
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system. Finally, observational studies, which are prone to
observer bias, should never be taken at face value, even if
they make headlines in the medical and lay media and even if,
in some instances, they might be hypothesis generating. The
analysis of Leenen et al4 puts a definite end to what was
called the CCB controversy, which flourished for more than
a decade. Only randomized trials provide evidence strong
enough to be useful in the management of hypertensive patients,
which currently already represent 20% to 30% of the world’s
population, a proportion likely to steadily increase over the next
decades.
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